Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narrative review synthesizing adverse event profiles across 14 NCCN-recommended systemic therapies for cutaneous T-cell lymphoma, designed to inform clinical treatment selection and monitoring rather than report new efficacy data.
Large national cohort study with 34,427 consecutive CLL diagnoses, multivariable analysis adjusting for key confounders, and hard clinical endpoints (overall and cause-specific survival) demonstrating previously unreported socioeconomic and geographic disparities.
This is an editorial review synthesizing current knowledge on ALK-directed immunotherapies for pediatric tumors, providing expert perspective on emerging approaches rather than reporting original clinical trial data.
A White Paper outlining strategic recommendations and a roadmap for international registry collaboration in lymphoma, not reporting original research findings or clinical trial data.
Retrospective analysis of 109 patients showing statistically significant survival benefits with chemotherapy integration in ALK-positive NSCLC, but limited by observational design, potential confounding, and lack of randomization.
This is an editorial commentary describing a resource paper, not a primary research study reporting empirical findings, effect sizes, or clinical outcomes to evaluate.
A single case report describing a rare presentation of CNS lymphoma with novel molecular findings; raises diagnostic and clinical awareness but provides no comparative data or outcome evidence.